{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:52:56Z","timestamp":1781571176531,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz Medical University","doi-asserted-by":"publisher","award":["70181"],"award-info":[{"award-number":["70181"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.humimm.2024.110798","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T23:52:13Z","timestamp":1712015533000},"page":"110798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Everolimus treatment enhances inhibitory immune checkpoint molecules\u2019 expression in monocyte-derived dendritic cells"],"prefix":"10.1016","volume":"85","author":[{"given":"Bahar","family":"Naseri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Mardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Khosrojerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Baghbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Aghebati-Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Hatami-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad Ahmadian","family":"Heris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Eskandarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Kafshdouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-1177","authenticated-orcid":false,"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.110798_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.humimm.2024.110798_b0010","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.4049\/jimmunol.1601629","article-title":"The importance of dendritic cells in maintaining immune tolerance","volume":"198","author":"Audiger","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110798_b0015","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110798_b0020","doi-asserted-by":"crossref","first-page":"20220053","DOI":"10.1360\/nso\/20220053","article-title":"Dendritic cell maturation in the tumor microenvironment","volume":"2","author":"Miao","year":"2023","journal-title":"Natl. Sci. Open"},{"key":"10.1016\/j.humimm.2024.110798_b0025","article-title":"Application of dendritic cells in tumor immunotherapy and progress in the mechanism of anti-tumor effect of astragalus polysaccharide (APS) modulating dendritic cells: a review","volume":"113541","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.humimm.2024.110798_b0030","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3389\/fimmu.2017.01764","article-title":"Tolerance through education: how tolerogenic dendritic cells shape immunity","volume":"8","author":"Domogalla","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110798_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120466","article-title":"Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: from bench to bedside","volume":"297","author":"Ghorbaninezhad","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1189\/jlb.0613336","article-title":"Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation","volume":"95","author":"\u0160vajger","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.humimm.2024.110798_b0045","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.humimm.2024.110798_b0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.humimm.2024.110798_b0055","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0065","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","volume":"16","author":"Houghton","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.carrev.2014.05.007","article-title":"Effects of everolimus on macrophage-derived foam cell behavior","volume":"15","author":"Hsu","year":"2014","journal-title":"Cardiovasc Revasc Med."},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1515\/bmc-2021-0006","article-title":"Everolimus-induced effector mechanism in macrophages and survivability of Erdman, CDC1551 and HN878 strains of mycobacterium tuberculosis infection","volume":"12","author":"Cao","year":"2021","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.humimm.2024.110798_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2013.00082","article-title":"Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells","volume":"4","author":"Hubo","year":"2013","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110798_b0085","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.immuni.2010.10.007","article-title":"Designing vaccines based on biology of human dendritic cell subsets","volume":"33","author":"Palucka","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2024.110798_b0090","first-page":"e54128","article-title":"Generation of immature, mature and tolerogenic dendritic cells with differing metabolic phenotypes","volume":"112","author":"Sim","year":"2016","journal-title":"JoVE (journal of Visualized Experiments)."},{"issue":"9","key":"10.1016\/j.humimm.2024.110798_b0095","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20090746","article-title":"Feedback control of regulatory T cell homeostasis by dendritic cells in vivo","volume":"206","author":"Darrasse-J\u00e8ze","year":"2009","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.humimm.2024.110798_b0100","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"S\u00e4emann","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0105","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.humimm.2024.110798_b0110","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.humimm.2024.110798_b0115","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1185\/03007995.2013.846253","article-title":"Everolimus: a new hope for patients with breast cancer","volume":"30","author":"Sendur","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.humimm.2024.110798_b0125","doi-asserted-by":"crossref","unstructured":"M\u00e1rtinez J, Pulido L, Bellido C, Usero D, Aguilar L, Moreno J, et al., editors. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. Transplantation proceedings; 2010: Elsevier.","DOI":"10.1016\/j.transproceed.2010.02.011"},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.humimm.2024.110798_b0135","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","article-title":"Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses","volume":"75","author":"Majewski","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110798_b0140","doi-asserted-by":"crossref","unstructured":"Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein\u2013Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proceedings of the National Academy of Sciences. 2000;97(8):4285-90.","DOI":"10.1073\/pnas.080068597"},{"key":"10.1016\/j.humimm.2024.110798_b0145","unstructured":"Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Current opinion in investigational drugs (London, England: 2000). 2002;3(2):295-304."},{"issue":"10","key":"10.1016\/j.humimm.2024.110798_b0150","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and molecular effects of the mTOR inhibitor everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin. Sci."},{"issue":"9637","key":"10.1016\/j.humimm.2024.110798_b0155","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.110798_b0160","doi-asserted-by":"crossref","unstructured":"Barten M, Garbade J, Bittner H, Richter M, Dhein S, Mohr F, et al. Everolimus suppresses dendritic cell maturation in human heart transplanted recipients. The Thoracic and Cardiovascular Surgeon. 2006;54(S 1):PP_84.","DOI":"10.1055\/s-2006-925866"},{"key":"10.1016\/j.humimm.2024.110798_b0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10495-017-1391-1","article-title":"Multi-targeted therapy of everolimus in Kaposi\u2019s sarcoma associated herpes virus infected primary effusion lymphoma","volume":"22","author":"Mohanty","year":"2017","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0170","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/viro.2000.0445","article-title":"Production of functionally deficient dendritic cells from HTLV-I-infected monocytes: implications for the dendritic cell defect in adult T cell leukemia","volume":"274","author":"Makino","year":"2000","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.humimm.2024.110798_b0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/imm.12035","article-title":"The combination of I\u03baB kinase \u03b2 inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells","volume":"138","author":"Nishioka","year":"2013","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.humimm.2024.110798_b0180","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2013.337","article-title":"Rapamycin induces ILT3(high)ILT4(high) dendritic cells promoting a new immunoregulatory pathway","volume":"85","author":"Stallone","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.humimm.2024.110798_b0185","doi-asserted-by":"crossref","unstructured":"Quentin J, Charbonnier L-M, Martire D, Mausset-Bonnefont A-L, Jorgensen C, Louis-Plence P. Rapamycin-induced alteration of the DC maturation process sustains their capacity to induce regulatory T cells. Annals of the Rheumatic Diseases. 2011;70(Suppl 2):A70-A.","DOI":"10.1136\/ard.2010.149013.7"},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007890-200301150-00025","article-title":"Rapamycin impairs antigen uptake of human dendritic cells","volume":"75","author":"Monti","year":"2003","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.humimm.2024.110798_b0195","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jbm.a.31373","article-title":"Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells","volume":"84","author":"Haddadi","year":"2008","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"3","key":"10.1016\/j.humimm.2024.110798_b0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/cei.12191","article-title":"Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions","volume":"174","author":"Boor","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110798_b0205","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.4049\/jimmunol.1302498","article-title":"Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function","volume":"193","author":"Amiel","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0210","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.4049\/jimmunol.1103741","article-title":"Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice","volume":"189","author":"Amiel","year":"2012","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110798_b0215","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/cancers11050617","article-title":"mTOR inhibitors can enhance the anti-tumor effects of DNA vaccines through modulating dendritic cell function in the tumor microenvironment","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0220","first-page":"174","article-title":"Rapamycin induces apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages","volume":"98","author":"Woltman","year":"2001","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"11","key":"10.1016\/j.humimm.2024.110798_b0225","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2002-11-3370","article-title":"Rapamycin inhibits IL-4\u2014induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo","volume":"101","author":"Hackstein","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.humimm.2024.110798_b0230","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.4049\/jimmunol.178.11.7018","article-title":"Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance","volume":"178","author":"Turnquist","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110798_b0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of Treg cell differentiation and function by the Interleukin-21-mechanistic target of rapamycin Axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"35","key":"10.1016\/j.humimm.2024.110798_b0240","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41388-019-0877-4","article-title":"Inhibition of mTOR complex 1\/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced \u03b2-TrCP degradation","volume":"38","author":"Deng","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trim.2012.11.005","article-title":"Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM\/BTLA\/CD160\/LIGHT pathway in allo-renal recipients","volume":"28","author":"Bai","year":"2013","journal-title":"Transpl. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imm.12354","article-title":"The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts","volume":"144","author":"Urbanellis","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.humimm.2024.110798_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.682627","article-title":"B7\u2013H7 is inducible on T cells to regulate their immune response and serves as a marker for exhaustion","volume":"12","author":"Luu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110798_b0260","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12032-021-01624-5","article-title":"The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer","volume":"39","author":"Xia","year":"2022","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.humimm.2024.110798_b0265","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.4049\/jimmunol.1000296","article-title":"A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation","volume":"185","author":"Haidinger","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110798_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152031","article-title":"Modulatory effect of rapamycin and tacrolimus on monocyte-derived dendritic cells phenotype and function","volume":"226","author":"Dahlqvist","year":"2021","journal-title":"Immunobiology"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:02:08Z","timestamp":1781568128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0198885924000582"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110798","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus treatment enhances inhibitory immune checkpoint molecules\u2019 expression in monocyte-derived dendritic cells","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110798"}}